Manuel Antonio Espinoza Sepulveda
Profesor Asociado
PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE
Santiago, Chile
Economic evaluation in health; Decision making of funding health interventions; Patient participation in healthcare decision making; Multicriteria approaches to decision making about allocating resources in healthcare; Managed Entry Agreements
-
Magíster en Bioestadística, UNIVERSIDAD DE CHILE. Chile, 2007
-
Magíster en Epidemiología, PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE. Chile, 2008
-
Master of Science in Health Economics, THE UNIVERSITY OF YORK. Reino Unido, 2009
-
PhD in Economics, THE UNIVERSITY OF YORK. Reino Unido, 2012
-
Médico Cirujano, PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE. Chile, 2004
-
Associate Professor Full Time
PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE
Medicine
Santiago, Chile
2008 - At present
-
Associate Professor Full Time
Pontificia Universidad Católica de Chile
Chile
2008 - At present
-
Asesor Científico Part Time
Institute of Public Health of Chile
Chile
2013 - 2015
-
Doctor in services of Internal Medicine and Emergency Part Time
Hospital de Urgencias Asistencia Pública
Santiago, Chile
2004 - 2008
-
Research Fellow
University of York
Reino Unido
2012 - 2012
-
Consulting Other
Intermamerican Bank of Development
Estados Unidos
2021 - At present
-
Retainer Consultant Other
United Nations Office for Project Services
Estados Unidos
2021 - At present
-
Chair HTAi Latinamerica Policy Forum Other
Health Technology Assessment International
Canada
2022 - At present
-
Editor in Chief Value in Health Regional Issues Other
International Society for Pharmacoeconomics and Outcomes Research
Estados Unidos
2020 - At present
Supervisor of thesis
8 (finished) Thesis of the Master in Health Administration
4 (finished) Thesis of the Master in Epidemiology
1 (finished) Doctoral thesis in Public Health
1 (ongoing) Thesis of the Master in Epidemiology
1 (ongoing) Doctoral thesis in Health Economics (University of Technology Sidney, Australia)
Head of the course.
Health Economics- Master in Health Administration
Economic evaluation and health technology assessment - Master in Health Administration
Health economics and economic evaluation - Master in Public Health
Decision-making in healthcare - Course for residents in clinical specialities
Diploma
Director Diploma in economic evaluation of healthcare technologies
Participation in Scientific Societies
1. Member of the Internacional Board of the International society for Pharmacoeconomics and Outcomes Research (ISPOR)
2. President Latinoamerican ISPOR Consortia
3. President ISPOR Chile Chapter
4. Member organizing committee of Latinamerican ISPOR Congresses (Buenos Aires 2013, Santiago 2015, Sao Paulo 2017)
Editorial roles
5. Ex editor in Chief ISPOR Newsletter "News Across Latinamerica"
6. Ex co-editor of Value in health, the top journal of ISPOR (Impact factor above 5)
7. Editor in Chief Value in Health Regional Issues (during his mandate the journal was indexed in WOS)
Manuel performs more than 30 conferences on economic evaluation, priority setting in health, patient participation, and decision-making processes in Chile and abroad. These talks include oral presentations and participation as a speaker in international congresses, talks to specific groups (medical specialists, patient representatives, pharmacists, innovation industry and payers)
Participation and collaboration with public entities
1. Expert in the working group to create the national guidelines for economic evaluation.
2. Member of the National Commission for Health Technology Assessment (2013)
3. Collaborator of the Ministry of Health to estimate the demand for palliative care in Chile,
4. Expert in the working group convened by the undersecretary of health to generate a proposal for a new institute of Health Technology Assessment.
-
Best Student Master in Biostatistics
UNIVERSIDAD DE CHILE
Chile, 2007
Best mark of teh year
-
Young Physician Leader 2017
ACADEMIA CHILENA DE MEDICINA
Chile, 2017
Elegido por la Academia Chilena de Medicina y luego por el Network Mundial de Academias de Medicina como Young Physician Leader version 2017
-
Best oral research presentation
International Society for Pharmacoeconomics and Outcomes Research
España, 2011
Prize for the best oral presentation. Work titled "The value of heterogeneity for cost-effectiveness subgroup analysis".
-
Best oral research presentation
International Society for Pharmacoeconomics and Outcomes Research
Estados Unidos, 2012
Best oral research presentation. Work titled "Individual Decisions and Social Value: A Conceptual Framework to Explore Alternative Decision Making Approaches and the Value of Heterogeneity in the Era of Individualized Care".
Manual para la participación de pacientes en toma de decisiones sobre cobertura en salud |
Plasma polyphenols and antioxidants, oxidative DNA damage and endothelial function in a diet and wine intervention study in humans |
The Link Between Information and Communication Technologies and Global Public Health: Pushing Forward |
Análisis y propuesta de un proceso de evaluación de tecnologías en salud (ETESA) para informar la toma de decisiones sobre cobertura en salud en Chile |
Costo efectividad de ureterolitectomia endoscópica comparado con litotrisia extracorpórea y tratamiento médico expulsivo para el tratamiento de cálculos menores de 10 mm en pacientes con litiasis ureteral |
Costo-efectividad de nuesvas estrategias de tamizaje de cancer de mama |
Evalaución económica del tratamiento de la atritis reumatoide con terapia biológica en Chile |
Participación de grupos de pacientes en procesos de toma de decisiones sobre cobertura en salud en Chile=> Explorando desafíos y oportunidades |
ESTUDIO COSTO EFECTIVIDAD Y DE IMPACTO PRESUPUESTARIO DE NIVOLUMAB EN EL TRATAMIENTO DEL MELANOMA METASTASICO EN EL SISTEMA DE SALUD DE CHILE |
ESTUDIO COSTO EFECTIVIDAD Y DE IMPACTO PRESUPUESTARIO DE RUXOLITINIB EN EL TRATAMIENTO DE LA MIERLOFIBROSIS EN EL SISTEMA DE SALUD DE CHILE |
ESTUDIO DE CARGA DE ENFERMEDAD Y COSTO CONSECUENCIA DEL DOLOR CRÓNICO DE ORIGEN OSTEO-MUSCULAR DESDE LA PERSPECTIVA DEL SISTEMA DE SALUD DE CHILE |
ESTUDIO DE COSTO EFECTIVIDAD E IMPACTO PRESUPUESTAL DE SUNITINIB EN EL TRATAMIENTO DE CARCINOMA RENAL METASTASICO EN CHILE |
EVALUACIÓN ECONÓMICA Y ANÁLISIS DE IMPACTO PRESUPUESTARIO DE LCZ696 EN EL TRATAMIENTO DE LA INSUFICIENCIA CARDIACA EN EL SISTEMA DE SALUD DE CHILE |
EVALUACIÓN ECONÓMICA Y ANÁLISIS DE IMPACTO PRESUPUESTARIO DE OMALIZUMAB EN EL TRATAMIENTO DE LA ASMA ALERGICA PERSISTENTE SEVERA |
EVALUACIÓN ECONÓMICA Y ANÁLISIS DEL IMPACTO PRESUPUESTARIO DE DAPAGLIFOZINA EN EL TRATAMIENTO DE LA DIABETES MELLITUS TIPO II, EN EL SISTEMA DE SALUD EN CHILE. |
ESTUDIO DE COSTO EFECTIVIDAD E IMPACTO PRESUPUESTAL DE DACLATASVIR/ASUNAPREVIR PARA EL TRATAMIENTO DE PACIENTES CON INFECCION CRÓNICA POR VIRUS HEPATITIS C GENOTIPO 1. |
Evaluación de costo-efectividad de Daclatasvir/Asunaprevir para el tratamiento de la infección crónica por virus Hepatitis C |
Anomalías congénitas y trastornos del desarrollo=> Evaluación de costo-efectividad de las nuevas herramientas diagnósticas. |
Tamizaje de cáncer de colon y recto=> análisis de costo efectividad para el sistema de salud público chileno. |
INFECCIÓN URINARIA EN PACIENTES TRASPLANTADOS RENALES |
Real-World Evidence in Healthcare Decision Making: Global Trends and Case Studies From Latin America |
How you measure social position in health research? A review of international literature |